GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » Debt-to-Revenue

Verici Dx (LSE:VRCI) Debt-to-Revenue : 0.07 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Verici Dx Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Verici Dx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was £0.15 Mil. Verici Dx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was £0.22 Mil. Verici Dx's annualized Revenue for the quarter that ended in Jun. 2024 was £5.25 Mil. Verici Dx's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.07.


Verici Dx Debt-to-Revenue Historical Data

The historical data trend for Verici Dx's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Debt-to-Revenue Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
N/A N/A N/A 0.53

Verici Dx Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial N/A N/A 16.40 0.27 0.07

Competitive Comparison of Verici Dx's Debt-to-Revenue

For the Diagnostics & Research subindustry, Verici Dx's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Verici Dx's Debt-to-Revenue falls into.


;
;

Verici Dx Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Verici Dx's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.129 + 0.298) / 0.8
=0.53

Verici Dx's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.145 + 0.215) / 5.248
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.


Verici Dx Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Verici Dx's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines